Clinical immunity
Th₁ - CD_11c⁺ B cell axis associated with response to plasmapheresis in multiple sclerosis
Ann Neurol. 2021 Oct;90(4):595-611.
Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry
Kimitoshi Kimura
Our repertoire analysis was used in the study of multiple sclerosis. The paper reports that plasmapheresis reduced Th1 cell inflammation-related gene expression in patients with multiple sclerosis. Furthermore, when a repertoire analysis was performed on CD_11c⁺ B cells in which IFN-γ expression in Th1 cells is associated with several autoimmune diseases, it was reported that there was a positive correlation, and diversity was reduced.

Solid tumor
Tumor-infiltrating CD8⁺ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma
Cancer Immunol Immunother. 2021 Sep 7. doi: 10.1007/s00262-021-03048-6.
Department of Pathology, Sapporo Medical University School of Medicine
Masahiro Matsuki
Our repertoire analysis was used in the study of solid tumors. The diversity of cancer cells in the tumor tissue, that is, "intra-tumor heterogeneity," is reported using the tumor tissue of patients with clear cell type renal cell carcinoma. As a result of microscopically dividing the tumor tissue into high-grade and low-grade sites and performing repertoire analysis, neoantigen-specific T cells were profiled from infiltrating lymphocytes in the high-grade sites, and neoantigen was also identified. However, it was not detected in the low-grade site. Similarly, it has been reported that the tumor microenvironment differs between tissues separated into microscopically high-grade and low-grade sites within the same tumor, showing "intratumor heterogeneity."

Clinical immunity
Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19
Heliyon. 2021 Aug;7(8):e07748.
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine
Yohei Funakoshi
Our repertoire analysis was used in the study of infectious diseases. BCR repertoire analysis was performed using peripheral blood collected over time in COVID-19 patients, and changes in the BCR repertoire were monitored. Monitoring revealed a marked surge in some BCR genes during the patient's recovery phase. The fact that the BCR information that changed significantly from the BCR repertoire analysis was obtained suggests that the repertoire analysis may contribute to the development of a neutralizing antibody for COVID-19. Our researchers are participating in this analysis as co-authors.

Basal immunity
The thymoproteasome hardwires the TCR repertoire of CD8⁺ T cells in the cortex independent of negative selection
J Exp Med. 2021 Apr 5;218(4):e20201904.
Division of Experimental Immunology, Institute of Advanced Medical Sciences, University of Tokushima
Izumi Ohigashi
Our repertoire analysis was used in the study of basal immunity. TCR repertoire analysis of CD8⁺ T cells showed that the thymoproteasome had a positive selection independent of the negative selection in the thymus of CD8⁺ T cells.

Basal immunity
Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD
Cell Immunol. 2021 Sep;367:104410.
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University
Hidekazu Itamura
Our repertoire analysis was used in transplantation research. The effect of MEK inhibitor administration on T-cell response using humanized GVHD model mice is investigated. MEK inhibitors have been shown to maintain polyclonal T-cell repertoire after administration, confirming a different response than other immunosuppressive agents. Our researchers are participating in this analysis as co-authors.

Solid tumor
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
Sci Rep. 2021 Jul 6;11(1):13912.
Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.
Toshiki Iwai
Dr. Toshiki Iwai in Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co. has published a paper in "Scientific Reports" titled "Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab".

Solid tumor
Diversity and shared T‑cell receptor repertoire analysis in esophageal squamous cell carcinoma
Oncol Lett. 2021 Aug;22(2):618.
Department of Surgery, Kurume University School of Medicine
Tomoya Sudo
Our repertoire analysis was used in the study of squamous cell carcinoma of the esophagus (ESCC). The study examined whether the TCR repertoire of T-cell subsets infiltrating tumor tissue in ESCC patients differs between the highly immune-related and low-immune-related groups grouped by immunohistological analysis. In the highly related group, the TCR repertoire was more diverse than in the less related group, and multiple T cells common to the individuals in the highly related group were also found. It was also confirmed that the cancer-specific survival rate and the recurrence-free survival rate were significantly higher in the highly immune-related group in the identified high and low immune-related groups. It has been suggested that the prognosis of ESCC patients is influenced by the presence of immune-responsive cells and may be stratified by a T-cell subset.

Basal immunity
The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells
Commun Biol. 2021 Jun 7;4(1):694.
Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
Takeshi Ito
Our repertoire analysis was used in the study of iPS-derived T cells. The paper reports the results of a study in which TIL was produced from iPS cells and used for treatment in TIL transfer therapy in which tumor-infiltrating T cells (TIL) were cultured and re-introduced. It is suggested that iPS cell production technology may greatly contribute to the progress of TIL therapy. Our analysis technology is used as a method to confirm whether iPS cells have the same profiling as the source T cells.

Basal immunity
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors
Cancer Immunol Immunother. 2021 Dec;70(12):3557-3571.
Drug Discovery Research, Astellas Pharma Inc.
Mamoru Tasaki
Dr. Mamoru Tasaki in Drug Discovery Research, Astellas Pharma Inc. has published a paper in "Cancer Immunology, Immunotherapy" titled "IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors".